Medpace Holdings, Inc.(MEDP)Earnings, Financials & Key Ratios

MEDP•NASDAQ

$430.32

$12.29B mkt cap·28.2× P/E·Price updated May 6, 2026

SectorHealthcare IndustryDiagnostics & Research Sub-IndustryContract Research and Preclinical Services

AboutMedpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.Show more

Revenue$2.53B+20.0%
EBITDA$563M+18.3%
Net Income$451M+11.6%
EPS (Diluted)15.28+21.0%
Gross Margin30.06%-3.4%
EBITDA Margin22.25%-1.4%
Operating Margin21.14%-0.2%
Net Margin17.83%-7.0%
ROE70.23%+20.2%
ROIC154.86%+75.9%
Debt/Equity0.55+201.3%

Analysis→Technical→

MEDP Key Insights

Medpace Holdings, Inc. (MEDP) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓Excellent 3Y average ROE of 62.8%
✓Strong 5Y profit CAGR of 25.4%
✓FCF machine: 26.9% free cash flow margin
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 22.3%
✓Share count reduced 7.8% through buybacks

✗Weaknesses

✗Trading more than 30% below 52-week high
✗Expensive at 27.7x book value

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

MEDP Price & Volume

Medpace Holdings, Inc. (MEDP) stock price & volume — 10-year historical chart

Loading chart...

MEDP Growth Metrics

Medpace Holdings, Inc. (MEDP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years21.56%

5 Years22.27%

3 Years20.12%

TTM24.19%

Profit CAGR

10 Years-

5 Years25.42%

3 Years22.51%

TTM10.57%

EPS CAGR

10 Years-

5 Years31.81%

3 Years28.04%

TTM21.53%

Return on Capital

10 Years28.74%

5 Years44.63%

3 Years56.68%

Last Year65.72%

MEDP Recent Earnings

Medpace Holdings, Inc. (MEDP) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 12/12 qtrs (100%)●Beat Revenue 7/12 qtrs (58%)

Q2 2026Latest

Apr 22, 2026

EPS

$4.28

Est $3.74

+14.4%

Revenue

$707M

Est $698M

+1.3%

Q1 2026

Feb 9, 2026

EPS

$4.67

Est $4.19

+11.5%

Revenue

$708M

Est $689M

+2.8%

Q4 2025

Oct 22, 2025

EPS

$3.86

Est $3.53

+9.3%

Revenue

$660M

Est $641M

+2.9%

Q3 2025

Jul 21, 2025

EPS

$3.10

Est $2.98

+4.0%

Revenue

$603M

Est $539M

+12.0%

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	Apr 22, 2026	$4.28vs $3.74+14.4%	$707Mvs $698M+1.3%
Q1 2026	Feb 9, 2026	$4.67vs $4.19+11.5%	$708Mvs $689M+2.8%
Q4 2025	Oct 22, 2025	$3.86vs $3.53+9.3%	$660Mvs $641M+2.9%
Q3 2025	Jul 21, 2025	$3.10vs $2.98+4.0%	$603Mvs $539M+12.0%

Based on last 12 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	FCF Yield	Debt / Equity
ICLRICON Public Limited CompanyDirect Competitor	9.26B	121.32	12.73	1.99%	7.4%	6.32%	12.07%	0.38
CRLCharles River Laboratories International, Inc.Direct Competitor	9.15B	185.39	-63.71	-0.85%	-3.59%	-4.34%	5.67%	0.95
PRAProAssurance CorporationDirect Competitor	1.27B	24.66	24.91	-2.67%	4.69%	3.95%		0.33
HIMSHims & Hers Health, Inc.Direct Competitor	6.8B	26.33	51.63	59%	5.47%	23.73%	1.09%	2.07
IQVIQVIA Holdings Inc.Product Competitor	29.94B	176.42	22.50	5.87%	8.33%	22.11%	6.85%	2.44
NVCRNovoCure LimitedProduct Competitor	1.81B	15.88	-13.02	8.28%	-25.66%	-50.82%		0.85
TMOThermo Fisher Scientific Inc.Supply Chain	173.46B	466.76	26.31	3.91%	15.18%	13.23%	3.63%	0.76
DHRDanaher CorporationSupply Chain	123.6B	174.63	34.65	2.9%	14.89%	7.06%	4.26%	0.35

Compare MEDP vs Peers

Medpace Holdings, Inc. (MEDP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs ICLR

Most directly comparable listed peer for MEDP.

Scale Benchmark

vs TMO

Larger-name benchmark to compare MEDP against a more recognizable public peer.

Peer Set

Compare Top 5

vs ICLR, CRL, PRA, HIMS

MEDP Income Statement

Medpace Holdings, Inc. (MEDP) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Sales/Revenue	436.15M	704.59M	860.97M	925.92M	1.14B	1.46B	1.89B	2.11B	2.53B	2.68B
Revenue Growth %	3.46%	61.55%	22.19%	7.54%	23.38%	27.8%	29.17%	11.84%	19.97%	24.19%
Cost of Goods Sold	261.46M	489.06M	615.27M	647.2M	814.22M	1.03B	1.36B	1.45B	1.77B	1.9B
COGS % of Revenue	59.95%	69.41%	71.46%	69.9%	71.27%	70.38%	72.19%	68.88%	69.94%	-
Gross Profit	174.69M▲ 0%	215.53M▲ 23.4%	245.7M▲ 14.0%	278.73M▲ 13.4%	328.15M▲ 17.7%	432.44M▲ 31.8%	524.5M▲ 21.3%	656.3M▲ 25.1%	760.62M▲ 15.9%	778.59M▲ 0%
Gross Margin %	40.05%	30.59%	28.54%	30.1%	28.73%	29.62%	27.81%	31.12%	30.06%	29.07%
Gross Profit Growth %	1.5%	23.38%	14%	13.44%	17.73%	31.78%	21.29%	25.13%	15.89%	-
Operating Expenses	109.83M	114.48M	118.43M	111.68M	129.54M	153.74M	187.68M	209.44M	225.68M	215.68M
OpEx % of Revenue	25.18%	16.25%	13.76%	12.06%	11.34%	10.53%	9.95%	9.93%	8.92%	-
Selling, General & Admin	63.36M	75.68M	95.25M	92.16M	108.42M	131.4M	161.35M	180.18M	197.56M	187.58M
SG&A % of Revenue	14.53%	10.74%	11.06%	9.95%	9.49%	9%	8.56%	8.54%	7.81%	-
Research & Development	0	0	0	0	0	0	0	0	0	0
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	46.47M	38.8M	23.19M	19.53M	21.12M	22.34M	26.33M	29.25M	28.12M	4M
Operating Income	64.86M▲ 0%	101.05M▲ 55.8%	127.26M▲ 25.9%	167.04M▲ 31.3%	198.62M▲ 18.9%	278.7M▲ 40.3%	336.82M▲ 20.9%	446.87M▲ 32.7%	534.93M▲ 19.7%	562.91M▲ 0%
Operating Margin %	14.87%	14.34%	14.78%	18.04%	17.39%	19.09%	17.86%	21.19%	21.14%	21.02%
Operating Income Growth %	23.56%	55.8%	25.94%	31.26%	18.9%	40.32%	20.86%	32.67%	19.71%	-
EBITDA	111.33M	139.85M	150.45M	186.57M	219.73M	301.04M	363.15M	476.12M	563.06M	577.07M
EBITDA Margin %	25.53%	19.85%	17.47%	20.15%	19.23%	20.62%	19.26%	22.58%	22.25%	21.55%
EBITDA Growth %	0.66%	25.61%	7.58%	24.01%	17.78%	37%	20.63%	31.11%	18.26%	18.86%
D&A (Non-Cash Add-back)	46.47M	38.8M	23.19M	19.53M	21.12M	22.34M	26.33M	29.25M	28.12M	14.16M
EBIT	64.5M	101.05M	127.26M	167.04M	198.62M	278.7M	336.82M	446.87M	542.38M	565.71M
Net Interest Income	-7.56M	-8.16M	-1.57M	307K	-105K	-2.9M	-488K	25M	0	7.71M
Interest Income	0	0	0	307K	0	0	0	25M	0	7.71M
Interest Expense	7.56M	8.16M	1.57M	0	105K	2.9M	488K	0	0	0
Other Income/Expense	-7.91M	-7.1M	-2.43M	1.49M	3.24M	4.16M	-1.14M	29.05M	7.44M	8.88M
Pretax Income	56.95M▲ 0%	93.95M▲ 65.0%	124.83M▲ 32.9%	168.53M▲ 35.0%	201.85M▲ 19.8%	282.86M▲ 40.1%	335.68M▲ 18.7%	475.92M▲ 41.8%	542.38M▲ 14.0%	571.8M▲ 0%
Pretax Margin %	13.06%	13.33%	14.5%	18.2%	17.67%	19.37%	17.8%	22.57%	21.44%	21.35%
Income Tax	17.82M	20.77M	24.39M	23.15M	20M	37.49M	52.87M	71.54M	91.25M	111.4M
Effective Tax Rate %	31.3%	22.1%	19.54%	13.74%	9.91%	13.25%	15.75%	15.03%	16.82%	19.48%
Net Income	39.12M▲ 0%	73.19M▲ 87.1%	100.44M▲ 37.2%	145.38M▲ 44.7%	181.85M▲ 25.1%	245.37M▲ 34.9%	282.81M▲ 15.3%	404.39M▲ 43.0%	451.12M▲ 11.6%	460.4M▲ 0%
Net Margin %	8.97%	10.39%	11.67%	15.7%	15.92%	16.81%	15%	19.17%	17.83%	17.19%
Net Income Growth %	191.41%	87.07%	37.25%	44.74%	25.08%	34.93%	15.26%	42.99%	11.56%	10.57%
Net Income (Continuing)	39.12M	73.19M	100.44M	145.38M	181.85M	245.37M	282.81M	404.39M	451.12M	460.4M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)	0.98▲ 0%	1.97▲ 101.0%	2.67▲ 35.5%	3.84▲ 43.8%	4.81▲ 25.3%	7.28▲ 51.4%	8.88▲ 22.0%	12.63▲ 42.2%	15.28▲ 21.0%	15.90▲ 0%
EPS Growth %	164.86%	101.02%	35.53%	43.82%	25.26%	51.35%	21.98%	42.23%	20.98%	21.53%
EPS (Basic)	1.00	2.05	2.79	4.07	5.06	7.57	9.20	13.06	15.64	-
Diluted Shares Outstanding	39.84M	36.91M	37.58M	37.71M	37.7M	33.67M	31.84M	32.01M	29.53M	28.96M
Basic Shares Outstanding	39.06M	35.55M	35.88M	35.63M	35.86M	32.39M	30.72M	30.96M	28.85M	28.45M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

MEDP Balance Sheet

Medpace Holdings, Inc. (MEDP) balance sheet — assets, liabilities & shareholders' equity

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Total Current Assets	129.97M	178.11M	317.03M	473.65M	690.91M	333.96M	593.83M	1.03B	989.62M	1.14B
Cash & Short-Term Investments	26.48M	23.27M	131.92M	277.77M	461.3M	28.27M	245.45M	669.44M	497.05M	652.68M
Cash Only	26.48M	23.27M	131.92M	277.77M	461.3M	28.27M	245.45M	669.44M	497.05M	652.68M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	83.08M	133.45M	155.66M	160.96M	186.43M	253.4M	298.4M	296.44M	402.08M	394.58M
Days Sales Outstanding	69.53	69.13	65.99	63.45	59.57	63.35	57.75	51.3	58	52.73
Inventory	7K	7K	0	0	0	0	0	0	0	0
Days Inventory Outstanding	0.01	0.01	-	-	-	-	-	-	-	-
Other Current Assets	7K	7K	0	0	0	52.29M	49.98M	63.35M	90.5M	91.79M
Total Non-Current Assets	820.75M	789.82M	826.04M	917.03M	969.02M	1.02B	1.06B	1.07B	985.85M	990.56M
Property, Plant & Equipment	48.74M	52.26M	99.44M	198.83M	222.71M	248.92M	265.39M	252.26M	248.87M	263.36M
Fixed Asset Turnover	8.95x	13.48x	8.66x	4.66x	5.13x	5.87x	7.11x	8.36x	10.17x	10.36x
Goodwill	660.98M	660.98M	662.4M	662.4M	662.4M	662.4M	662.4M	662.4M	662.4M	662.4M
Intangible Assets	98.74M	69.18M	54.35M	46.47M	41.36M	38.01M	35.81M	34.37M	33.42M	33.27M
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	5.94M	6.69M	9.48M	8.79M	17.42M	21.13M	24.97M	22.25M	21.94M	99.78M
Total Assets	950.72M▲ 0%	967.93M▲ 1.8%	1.14B▲ 18.1%	1.39B▲ 21.7%	1.66B▲ 19.4%	1.35B▼ 18.5%	1.66B▲ 22.5%	2.1B▲ 26.8%	1.98B▼ 6.0%	2.13B▲ 0%
Asset Turnover	0.46x	0.73x	0.75x	0.67x	0.69x	1.08x	1.14x	1.00x	1.28x	1.44x
Asset Growth %	-2.9%	1.81%	18.09%	21.66%	19.36%	-18.52%	22.5%	26.8%	-5.97%	-27.76%
Total Current Liabilities	192.71M	257.03M	343M	440.11M	557.22M	803.47M	925.13M	1.1B	1.34B	1.35B
Accounts Payable	16.67M	16.74M	22.4M	26.55M	25.68M	33.07M	31.87M	32.53M	28.14M	34.43M
Days Payables Outstanding	23.28	12.49	13.29	14.97	11.51	11.75	8.54	8.17	5.8	6.36
Short-Term Debt	16.5M	0	0	0	0	50M	0	23.29M	23.21M	244.51M
Deferred Revenue (Current)	73.76M	147.94M	192.36M	255.66M	344.64M	462.73M	559.86M	710.59M	854.39M	2.5B
Other Current Liabilities	81.81M	36.2M	53.11M	63.73M	85.46M	118.74M	116.26M	115.27M	357.87M	1.07B
Current Ratio	0.67x	0.69x	0.92x	1.08x	1.24x	0.42x	0.64x	0.93x	0.74x	0.74x
Quick Ratio	0.67x	0.69x	0.92x	1.08x	1.24x	0.42x	0.64x	0.93x	0.74x	0.74x
Cash Conversion Cycle	46.26	56.64	-	-	-	-	-	-	-	46.37
Total Non-Current Liabilities	254.48M	121.2M	73.79M	144.79M	149.79M	162.64M	172.75M	170.77M	172.65M	186.28M
Long-Term Debt	205.11M	79.72M	0	0	0	0	0	0	113.64M	122.26M
Capital Lease Obligations	0	0	45.21M	115.14M	130.97M	138.87M	142.12M	126.23M	113.64M	479.91M
Deferred Tax Liabilities	560K	439K	12.85M	13.55M	1.08M	1.07M	2.4M	1.8M	9.65M	17.5M
Other Non-Current Liabilities	48.81M	41.04M	15.72M	16.09M	17.75M	22.7M	28.22M	42.73M	-64.29M	102.22M
Total Liabilities	447.19M	378.23M	416.79M	584.9M	707.01M	966.11M	1.1B	1.28B	1.52B	1.53B
Total Debt	221.61M	79.72M	45.21M	115.14M	130.97M	188.87M	142.12M	149.52M	250.5M	122.26M
Net Debt	195.13M	56.45M	-86.71M	-162.62M	-330.34M	160.6M	-103.33M	-519.91M	-246.55M	-530.42M
Debt / Equity	0.44x	0.14x	0.06x	0.14x	0.14x	0.49x	0.25x	0.18x	0.55x	0.55x
Debt / EBITDA	1.99x	0.57x	0.30x	0.62x	0.60x	0.63x	0.39x	0.31x	0.44x	0.21x
Net Debt / EBITDA	1.75x	0.40x	-0.58x	-0.87x	-1.50x	0.53x	-0.28x	-1.09x	-0.44x	-0.44x
Interest Coverage	8.53x	12.39x	81.16x	-	1891.57x	95.94x	690.22x	-	-	-
Total Equity	503.53M▲ 0%	589.7M▲ 17.1%	726.28M▲ 23.2%	805.78M▲ 10.9%	952.93M▲ 18.3%	386.39M▼ 59.5%	558.95M▲ 44.7%	825.54M▲ 47.7%	459.07M▼ 44.4%	598.31M▲ 0%
Equity Growth %	-17.55%	17.11%	23.16%	10.95%	18.26%	-59.45%	44.66%	47.7%	-44.39%	-187.71%
Book Value per Share	12.64	15.98	19.33	21.37	25.28	11.48	17.55	25.79	15.55	20.66
Total Shareholders' Equity	503.53M	589.7M	726.28M	805.78M	952.93M	386.39M	558.95M	825.54M	459.07M	598.31M
Common Stock	355K	356K	360K	355K	360K	309K	308K	306K	284K	286K
Retained Earnings	-120.4M	-41.49M	68.11M	115.23M	234.98M	-359.83M	-221.65M	8.17M	-459.98M	-336.11M
Treasury Stock	-6.03M	-6.03M	-6.03M	-5.58M	-5.43M	-12.5M	-12.32M	-12.23M	-12.16M	-12.16M
Accumulated OCI	-734K	-2.52M	-2.74M	-131K	-4.85M	-12.39M	-10.07M	-14.74M	-4.91M	-7.12M
Minority Interest	0	0	0	0	0	0	0	0	0	0

MEDP Cash Flow Statement

Medpace Holdings, Inc. (MEDP) cash flow — operating, investing & free cash flow history

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Cash from Operations	97.39M	156.58M	201.87M	258.68M	263.33M	388.05M	433.37M	608.82M	713.22M	713.22M
Operating CF Margin %	22.33%	22.22%	23.45%	27.94%	23.05%	26.58%	22.98%	28.87%	28.19%	-
Operating CF Growth %	6.16%	60.79%	28.92%	28.14%	1.8%	47.36%	11.68%	40.48%	17.15%	114.43%
Net Income	39.12M	73.19M	100.44M	145.38M	181.85M	245.37M	282.81M	404.39M	451.12M	460.4M
Depreciation & Amortization	46.47M	38.8M	23.19M	19.53M	21.12M	22.34M	26.33M	29.25M	27.18M	27.24M
Stock-Based Compensation	4.46M	6.5M	20.74M	13.78M	14.47M	21.41M	20.52M	25.51M	34.79M	12.27M
Deferred Taxes	3.24M	3.94M	10.05M	527K	-37.11M	-23.01M	-25.12M	-26.63M	80.77M	98.57M
Other Non-Cash Items	-8.79M	-5.44M	11.86M	13.2M	16.3M	15.89M	22.35M	19.11M	23.09M	34.23M
Working Capital Changes	12.88M	39.6M	35.59M	66.26M	66.71M	106.06M	106.49M	157.18M	96.28M	106.47M
Change in Receivables	-2.9M	-27.05M	-21.26M	-5.53M	-24.98M	-66.92M	-48.28M	2.24M	-106.22M	-96.32M
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	4.82M	1.34M	4.73M	-2.6M	1.87M	6.43M	1.05M	-2.96M	2.63M	-8.01M
Cash from Investing	-12.24M	-16.97M	-19.14M	-31.21M	-31.36M	-38.74M	-34.63M	-28.31M	-31.14M	-27.9M
Capital Expenditures	-11.72M	-16.02M	-17.91M	-31.34M	-28.27M	-36.88M	-36.65M	-36.55M	0	5.46M
CapEx % of Revenue	2.69%	2.27%	2.08%	3.38%	2.47%	2.53%	1.94%	1.73%	1.24%	-
Acquisitions	0	0	0	0	0	0	0	0	0	0
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-513K	-949K	-1.23M	126K	-3.09M	-1.86M	2.02M	8.24M	-31.14M	-33.36M
Cash from Financing	-97.83M	-141.58M	-73.92M	-82.28M	-44.45M	-775.77M	-182.64M	-154.01M	-860.39M	-501.75M
Debt Issued (Net)	57.63M	-142.19M	-80.44M	0	0	50M	-50M	0	0	0
Equity Issued (Net)	-155.58M	0	0	-98.27M	-62.1M	-847.85M	-144.02M	-169.87M	-860.39M	-510.09M
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-155.58M	0	0	-98.27M	-62.1M	-847.85M	-144.02M	-169.87M	-917.39M	-545.49M
Other Financing	130K	608K	6.52M	15.99M	17.64M	22.07M	11.38M	15.86M	0	8.34M
Net Change in Cash	-10.91M▲ 0%	-3.21M▲ 70.6%	108.64M▲ 3484.4%	145.85M▲ 34.2%	183.54M▲ 25.8%	-433.04M▼ 335.9%	217.18M▲ 150.2%	423.99M▲ 95.2%	-172.39M▼ 140.7%	211.25M▲ 0%
Free Cash Flow	85.09M▲ 0%	140.56M▲ 65.2%	183.96M▲ 30.9%	227.34M▲ 23.6%	235.06M▲ 3.4%	351.17M▲ 49.4%	396.73M▲ 13.0%	572.27M▲ 44.2%	681.87M▲ 19.2%	744.63M▲ 0%
FCF Margin %	19.51%	19.95%	21.37%	24.55%	20.58%	24.05%	21.04%	27.13%	26.95%	27.8%
FCF Growth %	8.82%	65.19%	30.87%	23.58%	3.4%	49.4%	12.97%	44.25%	19.15%	37.66%
FCF per Share	2.14	3.81	4.90	6.03	6.24	10.43	12.46	17.88	23.09	23.09
FCF Conversion (FCF/Net Income)	2.49x	2.14x	2.01x	1.78x	1.45x	1.58x	1.53x	1.51x	1.58x	1.62x
Interest Paid	6.89M	7.59M	1.49M	104K	123K	2.94M	3.06M	171K	0	0
Taxes Paid	17.18M	23.31M	13.23M	23.11M	56.24M	50.16M	76.35M	83.57M	0	0

MEDP Key Ratios

Medpace Holdings, Inc. (MEDP) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM
Return on Equity (ROE)	7.02%	13.39%	15.27%	18.98%	20.68%	36.64%	59.83%	58.42%	70.23%	120.89%
Return on Invested Capital (ROIC)	6.78%	11.27%	14.85%	19.53%	23.54%	35.74%	50.39%	88.05%	154.86%	154.86%
Gross Margin	40.05%	30.59%	28.54%	30.1%	28.73%	29.62%	27.81%	31.12%	30.06%	29.07%
Net Margin	8.97%	10.39%	11.67%	15.7%	15.92%	16.81%	15%	19.17%	17.83%	17.19%
Debt / Equity	0.44x	0.14x	0.06x	0.14x	0.14x	0.49x	0.25x	0.18x	0.55x	0.55x
Interest Coverage	8.53x	12.39x	81.16x	-	1891.57x	95.94x	690.22x	-	-	-
FCF Conversion	2.49x	2.14x	2.01x	1.78x	1.45x	1.58x	1.53x	1.51x	1.58x	1.62x
Revenue Growth	3.46%	61.55%	22.19%	7.54%	23.38%	27.8%	29.17%	11.84%	19.97%	24.19%

MEDP SEC Filings & Documents

Medpace Holdings, Inc. (MEDP) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

Apr 22, 2026·SEC

Material company update

Feb 9, 2026·SEC

Material company update

Oct 22, 2025·SEC

10-K Annual Reports

FY 2026

Feb 10, 2026·SEC

FY 2025

Feb 11, 2025·SEC

FY 2024

Feb 13, 2024·SEC

10-Q Quarterly Reports

FY 2026

Apr 23, 2026·SEC

FY 2025

Oct 23, 2025·SEC

FY 2025

Jul 22, 2025·SEC

MEDP Frequently Asked Questions

Medpace Holdings, Inc. (MEDP) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Medpace Holdings, Inc. (MEDP) reported $2.68B in revenue for fiscal year 2025. This represents a 823% increase from $290.0M in 2014.

Medpace Holdings, Inc. (MEDP) grew revenue by 20.0% over the past year. This is strong growth.

Yes, Medpace Holdings, Inc. (MEDP) is profitable, generating $460.4M in net income for fiscal year 2025 (17.8% net margin).

Dividend & Returns

Medpace Holdings, Inc. (MEDP) has a return on equity (ROE) of 70.2%. This is excellent, indicating efficient use of shareholder capital.

Medpace Holdings, Inc. (MEDP) generated $744.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More MEDP

Medpace Holdings, Inc. (MEDP) financial analysis — history, returns, DCA and operating performance tools

Full MEDP Stock Analysis

Analyst verdict, bull/bear case, risk factors and peer comparison

→

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

Medpace Holdings, Inc.(MEDP)Earnings, Financials & Key Ratios

MEDP Key Insights

✓Strengths

✗Weaknesses

MEDP Price & Volume

MEDP Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

MEDP Recent Earnings

MEDP Peer Comparison

Compare MEDP vs Peers

vs ICLR

vs TMO

Compare Top 5

MEDP Income Statement

MEDP Balance Sheet

MEDP Cash Flow Statement

MEDP Key Ratios

MEDP SEC Filings & Documents

8-K Announcements

10-K Annual Reports

10-Q Quarterly Reports

MEDP Frequently Asked Questions

Explore More MEDP

Full MEDP Stock Analysis

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation